Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma
Acquired resistance to immunomodulatory drugs is common in multiple myeloma patients, but rarely attributed to genetic alterations. Here, proteomic, phosphoproteomic and RNA sequencing analysis in five paired pre-treatment and relapse samples reveals a CDK6-regulated protein resistance signature.
Bibliographic Details
| Main Authors: |
Yuen Lam Dora Ng,
Evelyn Ramberger,
Stephan R. Bohl,
Anna Dolnik,
Christian Steinebach,
Theresia Conrad,
Sina Müller,
Oliver Popp,
Miriam Kull,
Mohamed Haji,
Michael Gütschow,
Hartmut Döhner,
Wolfgang Walther,
Ulrich Keller,
Lars Bullinger,
Philipp Mertins,
Jan Krönke |
|---|
| Format: | Article
|
|---|
| Language: | English |
|---|
| Published: |
Nature Portfolio
2022-02-01
|
|---|
| Series: | Nature Communications
|
|---|
| Online Access: | https://doi.org/10.1038/s41467-022-28515-1
|
|---|